ses, supporting a non-selective, universal patient approach, and represents a promising therapeutic target in this setting.”

Globally, CRC is the third-most commonly diagnosed malignancy and the second leading cause of cancer-related deaths.1 Merck chose mCRC as the first indication to assess the efficacy and safety of Precem-TcT because ~90% of colorectal cancers overexpress CEACAM5,2 and there is a high unmet clinical need in patients with metastatic colorectal cancer, especially among those who progressed on several previous therapies.3,4,5 Patients with advanced colorectal cancer typically face a challenging prognosis, with few options available for those whose disease continues to progress after three or more lines of therapy. Additionally, with progression, response to treatment and prognosis become increasingly worse over time.

Advancing the Future of Cancer Care

At Merck, we strive every day to improve the futures of people living with cancer
=*=*=*=*=*=
当前为第4/10页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页